Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy

▤ Summary

This article reviews the manufacturing challenges and scaling strategies for CAR T cell therapies. It explains how the field is moving from manual, open workflows toward closed, automated systems that can improve reproducibility and throughput. It also covers alternative approaches such as allogeneic products, nonviral gene delivery, faster expansion methods, and improved quality control testing. The article emphasizes that regulatory compliance, supply chain stability, and skilled GMP staffing remain major barriers to commercial scale-up.

▦ Linked Companies